1. Home
  2. DOCU vs VTRS Comparison

DOCU vs VTRS Comparison

Compare DOCU & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DocuSign Inc.

DOCU

DocuSign Inc.

HOLD

Current Price

$57.07

Market Cap

13.9B

Sector

Technology

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$12.85

Market Cap

14.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOCU
VTRS
Founded
2003
1961
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9B
14.2B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
DOCU
VTRS
Price
$57.07
$12.85
Analyst Decision
Buy
Hold
Analyst Count
17
6
Target Price
$86.57
$11.50
AVG Volume (30 Days)
3.1M
9.6M
Earning Date
12-04-2025
02-26-2026
Dividend Yield
N/A
3.73%
EPS Growth
N/A
N/A
EPS
1.44
N/A
Revenue
$3,158,892,000.00
$14,124,400,000.00
Revenue This Year
$10.02
N/A
Revenue Next Year
$6.81
$1.18
P/E Ratio
$39.38
N/A
Revenue Growth
8.45
N/A
52 Week Low
$56.63
$6.85
52 Week High
$99.30
$13.49

Technical Indicators

Market Signals
Indicator
DOCU
VTRS
Relative Strength Index (RSI) 26.77 64.61
Support Level $64.05 $12.68
Resistance Level $70.93 $13.49
Average True Range (ATR) 2.57 0.32
MACD -1.10 -0.00
Stochastic Oscillator 0.25 52.31

Price Performance

Historical Comparison
DOCU
VTRS

About DOCU DocuSign Inc.

Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: